Category Archives: Pharmacogenomics

Back to Browse Journals Pharmacogenomics and Personalized Medicine Volume 10

Kelly K Filipski,John D Murphy,Kathy J Helzlsouer

Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD, USA

Abstract: Pharmacogenomics has identified important druggene interactions that affect the safety and efficacy of medications. Direct-to-consumer genetic testing, when first introduced, included some pharmacogenomic-related genes. The current landscape of pharmacogenomic direct-to-consumer testing is reviewed. Prior published reviews of the literature were updated through February 2017 and a scan of the current availability of direct-to-consumer genomic testing by companies was conducted. Results of the review demonstrate a shift toward physician-approved ordering.

Keywords: pharmacogenomics, direct-to-consumer testing

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Read the original post:
Updating the landscape of direct-to-consumer pharmacogenomic testing - Dove Medical Press

(April 14, 2017)

Dear ESPT member,First of all, I would like to thank you for your continued support of the European Society for Pharmacogenomics and Personalized Therapy (ESPT). With this email, I would like to update you on the activities of ESPT, and inform you about interactions with you as members regarding the direction and strategies of our society. The ESPT Board has been strengthened in October 2016 by Dr .Sanja Stankovic (Belgrade, Serbia) and Csilla Sipeky (Turku, Finland). Sanja took over the general secretariat from Janja Marc, whereas Ingolf Cascorbi (Kiel, Germany) took over the treasurer position from Sofia Siest. Janja Marc has taken over the Educational Division activities from Vangelis Manolopoulos. The Division Scientific Research and Clinical Implementation will be split in two individual Divisions, with Ron van Schaik (NL) leading the Clinical Implementation Division, collaborating with the European Pharmacogenetic Implementation Consortium (www.eu-pic.net) whereas Marc Ansari (CH) will chair the Research Division. ESPT has now a new Executive office, located in Milan, giving us the opportunity to professionalize our society as well as having a physical headquarter for meetings. Address: ESPT Executive Office, Via Carlo Farini 81, 20159 Milano, ItalyThe ESPT society itself will maintain its main registration in France. As ESPT, have been active in 2017 in setting up and/or extending collaborations with the Finnish National Society for Pharmacogenetics , the Turkish Society for Pharmacogenetics and the Serbian Society for Pharmacogenetics. ESPT has been present at the CPIC meeting in Washington DC (March 15), the ASCPT Annual meeting (Washington DC, March 16-18) and the UK Pharmacogenomics & Stratified Medicine Network Meeting (March 23) in London, UK.The preparations for the ESPT Annual Meeting 2017 (Oct 4-7) in Catania, Sicily, are in full progress. At this moment, 90% of the invited speakers have confirmed. It is expected that registration will start in 6 weeks. Already, we received a lot of positive reactions to this meeting. Also, the ESPT General Assembly will take place in Catania. More information will follow shortly. In the next months, ESPT will be present at the QLAC meeting in Belgrade (April 19-21), the Global Genomic Medicine Alliance meeting (Athens, April 27-29) , the WPA Interzonal congress in Vilnius, Lithuania (May 4-6), the Pharmaceutical World Congress in Stockholm (May 21-24) and the Human Genome Variation Society meeting (Copenhagen, May 26). Hope this update will give you more insight in the developments ongoing!Kindest regards,

The Society

Continued here:
Home [www.esptnet.eu]

Akonni'splatform delivers accurate, multiplexed analysis in a low-cost format, offering a valuable solution for healthcare applications such as disease prediction and prevention, early diagnosis, identification of drug resistance, and treatment monitoring.

SANTA CLARA, California, Aug. 15, 2017 /PRNewswire/ -- Based on its recent analysis of microarrays in molecular diagnostics (MDx), Frost & Sullivan recognizes Akonni Biosystems, Inc. with the 2017 North America Frost & Sullivan Award for New Product Innovation. Akonni's integrated MDx system, TruDiagnosis, is revolutionizing the point-of-care molecular testing market by enabling target detection from a variety of sample types. TruDiagnosis is powered by TruArray, a patented 3D gel-drop microarray technology for sample screening that instantly indicates the presence of disease markers in real time. Frost & Sullivan believes that Akonni is properly positioned to serve the precision medicine revolution.

Click here for the full multimedia experience of this release - http://bit.ly/2wJbPPQ

"TruDiagnosis offers rapid, reliable multiplexed analysis at a lower overall cost per array," reports Frost & Sullivan Senior Research Analyst Sanchari Chatterjee Maity. "The company modified this platform by replacing the traditional glass substrate with a cost-effective plastic film substrate for printing arrays without requiring functionalized coatings. Akonni also enhanced the manufacturing process for reel-to-reel manufacturing of arrays on film to generate greater cost efficiencies."

TruDiagnosis consists of Akonni's proprietary TruDx Imagers, TruArray Assays, and TruTip sample prep kits and includes nucleic acid extraction as well as fully-automated gridding and data analysis software for patient reporting. The platform serves a range of applications such as pharmacogenomics, chronic human diseases (cancer), infectious diseases, extensive drug-resistant tuberculosis, upper respiratory infections, viral encephalitis, and hospital-acquired infections.

At the heart of the platform is the TruArray 3D gel-drop technology, which delivers efficient immobilization capacity due to the innovative spacing design of the immobilized molecules throughout the volume of the gel drop. This design boasts high hybridization efficiency, which helps achieve specific hybridization to obtain incredibly accurate data. The low-density microarrays can carry between 5 and 400 3D gel-drops per array.

TruDiagnosis has garnered considerable praise for its easy mode of operation and accurate results. The testing procedure involves dropping a few microliters of the DNA sample onto a microfluidic test slide the size of a stick of chewing gum. The sample then flows over an array of the 3D gel-drops with probes that test for the targets of interest; for example, Akonni's multi-drug resistant mycobacterium TB (MDR-TB) test includes six tuberculosis (TB) genes and 88 strain-specific mutations. Akonni facilitates workflows by combining conventional target amplification, fragmentation, and labeling processes into a single microfluidic chamber. Additionally, the integrated, self-contained design of the microfluidic device alleviates the risk of amplicon contamination following polymerase chain reaction (PCR) amplification. Once the assay is finished, the test is inserted in the TruDx reader, which detects and indicates a genetic match. This operational method takes significantly less computation time than other diagnostic microarrays.

Pre-clinical studies demonstrate the superiority of TruDiagnosis' clinical viability over traditional multiplexed platforms. "Akonni has won several projects from leading private as well as government entities in North America and Asia-Pacific due to the versatility of its diagnostic products," noted Chatterjee Maity. "Overall, it enjoys a solid market presence and is well positioned for higher growth due to its effective products, customer-friendly approach, strategic execution of business prospects, and cost effectiveness."

Each year, Frost & Sullivan presents this award to a company that develops an innovative product element by leveraging leading-edge technologies. The award recognizes the value-added features/benefits of the product and the increased ROI it affords customers, which, in turn, raises customer acquisition and overall market penetration potential.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About Akonni Biosystems, Inc.

Akonni Biosystems was founded in 2003 and has been issued 21 US and 36 International patents primarily covering sample preparation, microfluidic devices, bioinstrumentation, and integrated systems. Product development has been supported by a series of government grants and contracts from NIH, CDC, DOE, DOD, NIJ, and NSF. The company significantly advanced the original technology by improving the system's capabilities from sample preparation to test result. Commercial products in Akonni's near-term pipeline include rapid sample preparation technologies for nucleic acid extraction and multiplex panel assays for detecting clinically relevant genotypes for pharmacogenomics, human chronic diseases, and genotypes for infectious diseases such as multidrug-resistant tuberculosis (MDR-TB), extensively drug-resistant tuberculosis (XDR-TB), upper respiratory infections, viral encephalitis, and hospital-acquired infections (MRSA).

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion.

Contact:

Ana ArriagaP: 210.247.3823F: 210.348.1003E: rel="nofollow">ana.arriaga@frost.com

Read more:
Frost & Sullivan Awards Akonni Biosystems for its Groundbreaking TruDiagnosis Molecular Diagnostics Platform - Markets Insider

Sessions and Tracks

The 6thEuropeanConference on Predictive Preventive and Personalized Medicine & Molecular Diagnostics will be held on September 14-15, 2017 at Edinburgh, Scotland will be organized around the themeUnleashing the novel approaches in advancing Personalized Medicinewhichcomprises 23 Sessions/Tracksto outline the theme of the conference organized by conferenceseries LLCConferences. The main aim of the conference is to highlight the achievements and innovations in the various fields of Personalized Medicine across the globe.

Track 1: Molecular Diagnostics in Personalized Medicine

In personalized medicine molecular diagnostics is used for analysing of biological markers and also analysing by applying molecular biology to medical testing .This technique is used to diagnose and monitor disease,detect risk in individual patients .DNA sequencing is the process of determining the precise order of nucleotides within a DNA molecule .SNP genotyping is the measurement of genetic variations of single nucleotide polymorphism (SNPs) . which is the measurement of more general genetic variation.Gene expression profiling is used for the measurement of the activity of thousands of genes at once.

Relevant conferences:

InternationalConference on Medical Imaging & Diagnosis,May 09 - 10, 2016 ,Chicago,US. InternationalCancer Study & Therapy Conference, 46 April 2016 ,Baltimore,United States.Conference on Human Genetics 2015 October 06-10, 2015, Baltimore, United States. International Conference on Genomics and pharmacogenomics during September 12-14, 2016 Berlin, Germany . Nanomaterials and Nanobiotechnology Conference April 21-23, 2016 Dubai, UAE. Congress on Heart Failure Genetics, Genomics and Epigenetics 37 April 2016 , Snowbird, United States. International Cancer Study & Therapy Conference, 46 April 2016 , Baltimore, United States.

Related Associations:

Alzheimers and Dementia Testing for Earlier Diagnosis

Association for Molecular Pathology Establishes New Standard for Clinical Utility of Molecular Diagnostics

British In Vitro Diagnostics Association (BIVDA)

California Life Sciences Association- Molecular Diagnostics

American Board of Clinical Chemistry

Molecular Diagnostics Laboratory

Association for Molecular pathology

Track2: Biomarkers Personalized Medicine

In personalized medicine biomarkers and biological marker generally refers to a measurableindicator of some biological state or condition. This word refer to a substance the presence of which indicates the existence of aliving organism. Biochemical biomarkers are often used inclinical trials, Biomarkers used for personalized medicine are typically categorized as either prognostic or predictive .In , a biomarkersis a molecule that allows the detection and isolation of a particular cell type. A biomarker indicates a change in state of a protein that correlates with the risk or progression of a disease . Biomarkers are useful in a number of ways, including measuring the progress of disease. Biomarkers also used in early diagnosis, disease prevention, drug target identification, drug response etc.

Relevant conferences :

International conference on HIV/AIDS ,STDs & STIs from November 30-December 02, 2015 at Hilton Atlanta Airport, Atlanta, USA. Conference on Human Genetics 2015 October 06-10, 2015, Baltimore, United States. International Conference on Genomics and pharmacogenomics during September 12-14, 2016 Berlin, Germany . Nanomaterials and Nanobiotechnology Conference April 21-23, 2016 Dubai, UAE. Congress on Heart Failure Genetics, Genomics and Epigenetics 37 April 2016 , Snowbird, United States. International Conference on Medical Imaging & Diagnosis , May 09 - 10, 2016 , Chicago, US. .International Congress on Human Genetics and Genomics , Dec 8-9,2016, Rome ,Italy.

Related Associations:

ALS research Association

European society of cardiology

American Association of Pharmaceutical Scientists

American Board of Clinical Chemistry

Track3: Pharmacogenetic in Personalized Medicine

In personalized medicine pharmacogenetics is the study of inherited genetic differences in drug metabolic pathways which can affect the drug responses, like therapeutic effect as well as adverse effect. Inter- and intra-individual variation in gene expression and its function.In oncology, pharmacogenetics refers to germline mutations and pharmacogenomics is study the somatic mutations in tumoral DNA leading to alteration in drug response

Relevant conferences :

Nanomaterials and Nanobiotechnolog Conference April 21-23, 2016 Dubai, UAE. International Conference on Genomics and pharmacogenomics during September 12-14, 2016 Berlin, Germany. International conference on HIV/AIDS ,STDs & STIs from November 30-December 02, 2015 at Hilton Atlanta Airport, Atlanta, USA. International Cancer Study & Therapy Conference, 46 April 2016 , Baltimore, United States. Conference on Human Genetics 2015 October 06-10, 2015, Baltimore, United States.International Congress on Human Genetics and Genomics , Dec 8-9,2016, Rome , Italy. European Human Genetics Conference 2016 , May 21-24, 2016, Barcelona, Spain. World congress on Translation genomics,28 feb - 2 march, 2016,houstan, USA. Personalised Medicine Conference ,1-2 June,2016, Brussels, Belgium.

Related Associations:

European Society of Pharmacogenomics and Personalized Medicine

American Society of Human Genetics

Hungarian Society of Personalized Medicine

American Society for Investigative Pathology

Association for Molecular Pathology

Track4: Pharmacogenomics in Personalized Medicine

Pharmacogenomics is the study of the role of genetics in drug response. It deals with the influence of acquired and inheritedgeneticvariation on drug response, drug absorption distribution, metabolism, and elimination ,as well as drug receptor target effects . Pharmacogenomics is often used interchangeably with pharmacogenetics.Pharmacogenomics is used for the detection of the individual genetic variation with drug responses pharmacogenetics focuses on single drug-gene interactions, incorporating genomics and epigenetics while dealing with the effects of multiple genes on drug response

Relevant conferences :

International Conference on Medical Imaging & Diagnosis , May 09 - 10, 2016 , Chicago, US.International conference on HIV/AIDS ,STDs & STIs from November 30-December 02, 2015 at Hilton Atlanta Airport, Atlanta, USA. Conference on Human Genetics 2015 October 06-10, 2015, Baltimore, United States. International Conference on Genomics and pharmacogenomics during September 12-14, 2016 Berlin, Germany . Nanomaterials and Nanobiotechnology Conference April 21-23, 2016 Dubai, UAE. Congress on Heart Failure Genetics, Genomics and Epigenetics 37 April 2016 , Snowbird, United States. International Cancer Study & Therapy Conference, 46 April 2016 , Baltimore, United States.International Congress on Human Genetics and Genomics , Dec 8-9,2016, Rome ,Italy.

Related Associations:

Genetics societies

Canadian Association of genetics Counsellors

European Cytogeneticists Association

Human genome organization

International Genetic Epidemiology Society

British Society of Genetic Medicine

Track5: Pharmacoproteomics in Personalized Medicine

The proteome is the entire set of proteins it is expressed by genome , cell, tissue, or organism at a certain time. More specifically, it is a combined of proteins and genomes . Proteomics is the study of the proteome. A cellular proteome is the collection of proteins present in a particular cell type and it exposure to harmone stimulation . It can also be useful to consider an organisms complete proteome, which can be conceptualized as the complete set of proteins from all of the various cellular proteomes. Proteome used to refer to the collection of proteins in certain sub-cellular biological systems.

Relevant conferences:

International Congress on Human Genetics and Genomics , Dec 8-9,2016, Rome , Italy .European Human Genetics Conference 2016 , May 21-24, 2016, Barcelona, Spain .World congress on Translation genomics , 28feb - 2 march ,2016, houstan,USA . Personalised Medicine Conference ,1-2 June,2016, Brussels, Belgium. Nanomaterials and Nanobiotechnology Conference April 21-23, 2016 Dubai, UAE. International Conference on Genomics and pharmacogenomics during September 12-14, 2016 Berlin, Germany. International conference on HIV/AIDS ,STDs & STIs from November 30-December 02, 2015 at Hilton Atlanta Airport, Atlanta, USA. International Cancer Study & Therapy Conference, 46 April 2016 , Baltimore, United States. Conference on Human Genetics 2015 October 06-10, 2015, Baltimore, United States.

Related Associations:

International precision medicine Associates

International Society of Personalized Medicine

British Society for Proteome Research

European Proteomics Association

Swiss Proteomics Society

Japan Society for clinical Proteomics

Track6: Metabolomics in Personalized Medicine

Metabolomics is defined as the chemical processes involving of metabolites. Metabolomics is the study of the unique chemical fingerprints. The metabolome refers to the collection of all metabolites in a biological cell, tissue, organ or organism. mRNA gene expression data and proteomic analyses reveals the set of gene products in the cell. One of the challenges of system biology and functional genomics is to integrate proteomic ,transcriptomic, and metabolomic information to provide a cellular biology.

Relevant conferences :

Conference on Human Genetics 2015 October 06-10, 2015, Baltimore, United States. International Conference on Genomics and pharmacogenomics during September 12-14, 2016 Berlin, Germany. Nanomaterials and Nanobiotechnology Conference April 21-23, 2016 Dubai, UAE. Congress on Heart Failure Genetics, Genomics and Epigenetics 37 April 2016 , Snowbird, United States. International Cancer Study & Therapy Conference, 46 April 2016 , Baltimore, United States.International Congress on Human Genetics and Genomics , Dec 8-9,2016, Rome , Italy.

Related Associations:

Metabolomics Society

The Metabolomics Standards Initiative (MSI)

Metabolomics for a Low Carbon Society (METABOLOMICS)

Swiss Metabolomics Society

Metabolomics Research Group (MRG)

Track7: Personalized in Health Care

Personalized medicineis aMedical Practice that separates patients into different groups with medical decisions, practices, interventions and products being tailored to the individual patient based on their predicted response or risk of disease. The words of personalized medicine,precision medicine,stratified medicineand P4 medicine are used interchangeably .

Relevant conferences :

International Conference on Genomics and pharmacogenomics during September 12-14, 2016 Berlin, Germany. Nanomaterials and Nanobiotechnology Conference April 21-23, 2016 Dubai, UAE . International conference on HIV/AIDS ,STDs & STIs from November 30-December 02, 2015 at Hilton Atlanta Airport, Atlanta, USA. Conference on Human Genetics 2015 October 06-10, 2015, Baltimore , United States. Congress on Heart Failure Genetics, Genomics and Epigenetics 37 April 2016,Snowbird,United States . International Cancer Study & Therapy Conference, 46 April 2016 , Baltimore , United States. International Congress on Human Genetics and Genomics , Dec 8-9,2016, Rome , Italy. European Human Genetics Conference 2016 , May 21-24, 2016, Barcelona, Spain.

Related Associations:

American Health Care Association

Florida Health Care Association

OHCA Oregon Health Care Association

Texas Health care Association

Washington Health Care Association

Track8: Non- genomics Personalized Medicine

Epigenomics is a set of epigenetic modifications on the genetic material of a cell is called as the epigenome. Epigenetics are reversible modifications on a cells DNA that affect the gene expression without altering the DNA sequence. Epigenetic modifications are important role in the gene expression and regulation, that are involved in the numerous cellular processes such as tumorigenesis.

Relevant conferences:

Congress on Heart Failure Genetics, Genomics and Epigenetics 37 April 2016 , Snowbird,United States.International Conference on Medical Imaging & Diagnosis , May 09 - 10, 2016 , Chicago, US.International conference on HIV/AIDS ,STDs & STIs from November 30-December 02, 2015 at Hilton Atlanta Airport, Atlanta, USA. Conference on Human Genetics 2015 October 06-10, 2015, Baltimore, United States. International Conference on Genomics and pharmacogenomics during September 12-14, 2016 Berlin, Germany. Nanomaterials and Nanobiotechnology Conference April 21-23, 2016 Dubai, UAE. International Cancer Study & Therapy Conference, 46 April 2016 , Baltimore, United States.International Congress on Human Genetics and Genomics , Dec 8-9,2016, Rome , Italy.

Related Associations:

Genome Wide Association Studies (GWAS)

Genetics societies

Canadian Association of genetics Counsellors

European Cytogeneticists Association

Human genome organization

International Genetic Epidemiology Society

British Society of Genetic Medicine

German society of Human Genetics

Track9: Personalized Biological Therapies

Biological therapy refers to the use of medication , specifically target an immune or genetic mediator of disease. Even for diseases of unknown cause of molecules that are involved in the disease process have been identified, and can be targeted for biological therapy. which are mainly cytokines , are directly involved in the immune system .Biological therapy used for the management of cancer , autoimmune disease, and diseases of unknown cause that result in symptoms due to immune related mechanisms.

Relevant conferences :

International Conference on Medical Imaging & Diagnosis , May 09 - 10, 2016 , Chicago, US.International conference on HIV/AIDS ,STDs & STIs from November 30-December 02, 2015 at Hilton Atlanta Airport, Atlanta, USA. Conference on Human Genetics 2015 October 06-10, 2015, Baltimore, United States. International Conference on Genomics and pharmacogenomics during September 12-14, 2016 Berlin, Germany. Nanomaterials and Nanobiotechnology Conference April 21-23, 2016 Dubai, UAE. Congress on Heart Failure Genetics, Genomics and Epigenetics 37 April 2016 , Snowbird, United States. International Cancer Study & Therapy Conference, 46 April 2016 , Baltimore, United States.International Congress on Human Genetics and Genomics , Dec 8-9,2016, Rome , Italy.

Related Associations:

Human Biology Association

American Biological Safety Association

Society for Conversation Biology

Association for Tropical Biology

American Institute of Biological Sciences

American Society for Microbiology

Track10: Personalized Management of Cancer Therapy

More here:
Updated Scientific Program | Euro Personalized Medicine ...

Have you or a loved one ever had a bad reaction or unusual side effects when taking a medicine? Reading the long list of allergies, warnings, interactions and other possible complications on any prescription drug leaflet can be scary. Why is it that some drugs work great for some people but dont work well for others?

With 1,222 new drugs approved by the Food and Drug Administration (FDA) between 1950 and 2008, there are many options on the market (Munos, 2009, Nature Reviews Drug Discovery).With so many options, finding the right medication can be a drawn-out process of trial and error for the patient and the provider. As a result, complications are becoming alarmingly common. In 2015, the FDA received nearly 1.3 million reports ofdrug interactions, a rate that more than doubled in six years. Deaths from severe allergic reactions are also on the rise. *How your body reacts to any given medicine will be different from that of your spouse, your cousin, your best friend, your next-door neighbor, and your favorite grocery checkout clerk. (Reactions may even differ with the over-the-counter-drugs like aspirin or dietary supplements that the very same checkout clerkrang up for you!)

Read the original:
Genes Advice | Pharmacogenomics

This report describes different types of biomarkers and their discovery using various -omics technologies such as proteomics and metabolomics. Molecular diagnostics technologies are used for the discovery of biomarkers and new tests are also based on biomarker.

This report follows the broad definition of a biomarker as a characteristic that can be objectively measured and evaluated as an indicator of normal biological or pathogenic processes as well as pharmacological responses to a therapeutic intervention. Tests based on biomarkers have been around for more than half a century, but interest in their application for diagnostics and drug discovery as well as development has increased remarkably since the beginning of the 21st century.

Currently the most important applications of biomarkers are in drug discovery and development. The role of biomarkers in various therapeutic areas particularly cancer, cardiovascular diseases and disorders of the central nervous system, is described. Biomarkers are useful not only for diagnosis of some of these diseases but also for understanding the pathomechanism as well as a basis for development of therapeutics.

Biomarkers will facilitate the combination of therapeutics with diagnostics and will thus play an important role in the development of personalized medicine. Biomarkers play a role in use of pharmacogenetics, pharmacogenomics and pharmacoproteomics for development of personalized medicine.

Many of the regulatory issues concerning biomarkers are related to genomics, proteomics, molecular diagnostics and pharmacogenomics/pharmacogenetics. Validation of biomarkers and their role in clinical trials is discussed.

Biomarker markets are estimated from 2016 to 2026 according to share of markets for various technologies and applications: proteomics, metabolomics, molecular diagnostics, drug discovery, clinical trials, and bioinformatics. Market values are further split according to therapeutic applications and major geographical areas. Unfulfilled needs in biomarkers are identified as well as the drivers for biomarker markets. Challenges facing the biomarker industry and strategies for developing biomarker markets are discussed.

A large number of companies with varying technical backgrounds are involved in biomarkers and 304 of these are profiled in part 2 of the report with classification into various categories.These also include major pharmaceutical companies. There is tabulation of 467 collaborations between companies and additional academic collaborations are mentioned in the individual profiles of companies. The report is supplemented by 1,200 references, 77 tables and 20 figures

Key Topics Covered:

Part 1: Technologies & Markets

Executive Summary

1. Introduction

2. Technologies for Discovery of Biomarkers

3. Biomarkers and Molecular Diagnostics

4. Biomarkers for Drug Discovery & Development

5. Role of Biomarkers in Healthcare

6. Biomarkers of Cancer

7. Biomarkers of Disorders of the Nervous System

8. Biomarkers of Cardiovascular Disorders

9. Biomarkers & Personalized Medicine

10. Biomarkers and Regulatory issues

11. Markets for Biomarkers

12. References

Part II: Companies

13. Companies

For more information about this report visit https://www.researchandmarkets.com/research/4nrrhw/biomarkers

Source: Jain PharmaBiotech

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-biomarkers-technologies-markets-and-companies-projections-report-2017-300483376.html

SOURCE Research and Markets

http://www.researchandmarkets.com

Read the rest here:
Global Biomarkers Technologies, Markets and Companies Projections Report 2017 - PR Newswire (press release)